MVA-BN®
MVA-BN® (Modified Vaccinia Ankara - Bavarian Nordic) is a vaccine platform technology for addressing a wide variety of infectious diseases and cancers. It is a further attenuated version of the Modified Vaccinia Ankara (MVA) virus, which is a highly attenuated strain of the poxvirus Chorioallantois Vaccinia virus Ankara (CVA). MVA-BN® is approved as a smallpox vaccine in Canada and the EU (under the trade names IMVAMUNE® and IMVANEX® respectively).
Availability: Commercially Available
| Manufacturer |
| Bavarian Nordic, Inc. |
| Product Name |
| MVA-BN® |
| Detection Category |
| Biological |
| Detection Method |
| Medical Countermeasure; |
| Application |
| Personal Protective Equipment; |
| Equipment Type |
| PPE |
| Product Synopsis |
| MVA-BN® (Modified Vaccinia Ankara - Bavarian Nordic) is a vaccine platform technology for addressing a wide variety of infectious diseases and cancers. It is a further attenuated version of the Modified Vaccinia Ankara (MVA) virus, which is a highly attenuated strain of the poxvirus Chorioallantois Vaccinia virus Ankara (CVA). MVA-BN® is approved as a smallpox vaccine in Canada and the EU (under the trade names IMVAMUNE® and IMVANEX® respectively). |
| Availability |
| Commercially Available |
| Technology Readiness Level (TRL) |
| 9 |
| User Feedback Sources |
| Indifferent/No user feedback |
| Weight |
| <1 lb. |
| Power Requirements |
| None |
| Transportability |
| Pocket Size |
| Live Agent Tested |
| Yes; smallpox, Chorioallantois Vaccinia virus Ankara (CVA). |
| Operating Time |
| Preventative administration prior to exposure |
| Training Required |
| <1 hour training |
| Manuals Available |
| Yes |
